Please login to the form below
PureTech Health
This page shows the latest PureTech Health news and features for those working in and with pharma, biotech and healthcare.
Boehringer’s head of pharma heads for the exit
Carine Bruillon. Recent deals have included a 325m acquisition of AMAL Therapeutics to gain access to its cancer vaccine technology, a $226m alliance with UK-listed biotech PureTech Health to develop ... The reshuffle is extending into other business
Latest news
-
Boehringer posts solid first half as business revamp beds in
biotech PureTech Health to develop a new approach to cancer immunotherapy.
-
With Spiriva under pressure, Boehringer moves to bolster pipeline
Forges alliance with PureTech Health. Boehringer Ingelheim has forged a $226m alliance with UK-listed biotech PureTech Health to develop a new approach to cancer immunotherapy. ... Boehringer adds to an impressive list of big pharma partners for PureTech,
-
Voice biomarker device could diagnose depression, heart disease
Pharma), Neoteny 4, LP, Canepa Healthcare, and founder PureTech Health all participating as well. ... Eric Elenko, PhD, chief innovation officer at PureTech Health, said: “Sonde is pioneering an entirely new approach to health care with its proprietary
-
BMS and Celgene deal sparks debate on pharma profit motive, more M&A
Daphne Zohar, founder and CEO of PureTech Health was among those replying:.
-
BMS to test Vedanta’s bacterial therapy with Opdivo
PureTech Health subsidiary Vedanta specialises in developing bacterial consortia based on the organisms that naturally live in the human body, working on the premise that the organisms can impart healthful effects.
More from news
Approximately 4 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2017
PureTech Health has entered an agreement with Novartis to advance two clinical stage programmes in the field of immuno-senescence. ... Novartis. PureTech Health. Licence. mTORC1 inhibitors in phase IIa. 25. InGeneron.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
PureTech Health appoints new chief financial officer
Joep Muijrers joins the biopharma from Life Sciences Partners. Clinical-stage biopharmaceutical company PureTech Health has bolstered the team with a new chief financial officer in the form of Joep Muijrers. ... Daphne Zohar, founder and chief executive
-
John LaMattina joins Frequency Therapeutics in advisory role
Alongside his new role LaMattina will continue to serve as an independent non-executive director at PureTech Health.
-
Former GSK exec joins PureTech Health
Dr Atul Pande becomes chief medical officer. Boston, US-based PureTech Health has appointed Dr Atul Pande as its new chief medical officer, responsible for the firm's pipeline in immune, ... Dr Pande currently serves on the board of directors for Karuna
-
PureTech Health appoints chief scientific officer
Boston, US-based PureTech Health has appointed Dr Joseph Bolen as its chief scientific officer. ... Daphne Zohar, chief executive officer of PureTech Health, said: “We are tremendously excited to bring Joe's visionary leadership and drug development
-
PureTech appoints Joseph Bolen as entrepreneur-in-residence
And Vincent Hennemand joins as VP, company development and operations. Boston-based PureTech Health has appointed Joseph Bolen (pictured) as entrepreneur-in-residence. ... As PureTech's entrepreneur-in-residence he will work with the firm's company
More from appointments
Approximately 3 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- BMS eyes approval for second Opdivo combo in kidney cancer
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
